Neonatal Lupus Erythematosus

Autoimmune MONDO:0018360 Pathograph 11 Show in embeddings browser Autoimmune Disease Cardiac Conduction Disorder

Neonatal lupus erythematosus is a passively acquired autoimmune disease of the fetus and newborn caused by transplacental transfer of maternal IgG autoantibodies against the Ro/SSA and La/SSB ribonucleoproteins, and in a distinct subset against U1-RNP. Despite the name it is not systemic lupus erythematosus occurring in an infant: the affected child has no autoimmune disease of its own, produces no autoantibody, and recovers as maternal IgG is catabolised. Roughly half of the mothers are asymptomatic at delivery and are identified only by the birth of an affected child, so maternal lupus is not a prerequisite. The disease separates cleanly into two mechanistic halves that share one trigger. The transient half, comprising annular photosensitive skin lesions, cholestatic hepatitis and cytopenias, resolves over 6-12 months as antibody clears. The permanent half is cardiac: between 18 and 26 weeks of gestation, physiological remodelling of the developing atrioventricular conduction system exposes normally intracellular Ro and La antigens on the surface of apoptotic cardiocytes, maternal antibody binding diverts their clearance from neighbouring cardiocytes to professional phagocytes, and the resulting macrophage-myofibroblast crosstalk and TGF-beta-driven fibrosis replace conduction tissue irreversibly. This is why anti-inflammatory therapy can sometimes reverse incomplete block but never reverses established third-degree block, and it is what makes the disease a widely used model for studying how an autoantibody alone causes end-organ injury.

Ask OpenScientist

Ask a research question about Neonatal Lupus Erythematosus. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
6
Pathophys.
11
Phenotypes
2
Hypotheses
11
Pathograph
3
Genes
6
Medical Actions
1
Deep Research
👪

Inheritance

1
Not inherited (passively acquired)
Neonatal lupus is not transmitted as a Mendelian trait. The determinant of risk is the mother's antibody status, which is why recurrence in a subsequent pregnancy is high (of the order of 15-20% after an affected child) while the general population risk is negligible. That recurrence figure is often misread as a segregation ratio; it is not one, and no inheritance_term is bound here because the HPO mode-of-inheritance subtree has no value that correctly describes maternal-antibody transmission.
Show evidence (1 reference)
PMID:12139139 SUPPORT Human Clinical
"CHB occurs in approximately 1-5% of pregnancies in mothers with anti-Ro/La antibodies, independent of the mother's disease status, and in approximately 15-20% of pregnancies following the birth of a child with NLS."
States both the baseline per-pregnancy risk in antibody-positive mothers and the recurrence risk after an affected child, and makes explicit that risk tracks antibody status rather than maternal disease.
◈

Mechanistic Hypotheses

2
Diverted efferocytosis driving inflammatory fibrosis of the AV node
apoptosis_efferocytosis_fibrosis CANONICAL
Evidence balance 1 support
The mechanism this entry models in full. Maternal antibody bound to surface-exposed Ro/La on apoptotic cardiocytes blocks their silent clearance by neighbouring cardiocytes, diverting uptake to Fc-gamma-receptor-bearing macrophages, whose pro-inflammatory and pro-fibrotic secretion drives TGF-beta-mediated fibrosis and permanent replacement of conduction tissue. It is treated as canonical because it is the account with direct human tissue support: fibrosis, TGF-beta expression and macrophage-myofibroblast crosstalk have been observed in fetuses dying with congenital heart block.
Pathograph links
Surface Exposure of Ro/La Antigens on Apoptotic Fetal Cardiocytes -> Diverted Clearance of Opsonised Apoptotic Cardiocytes to Macrophages
Diverted Clearance of Opsonised Apoptotic Cardiocytes to Macrophages -> TGF-beta-Driven Fibrosis and Calcification of the Conduction System
Show evidence (1 reference)
PMID:18250129 SUPPORT Human Clinical
"The identification of exaggerated apoptosis, macrophage/myfibroblast crosstalk, TGF beta expression, and extensive fibrosis in the conducting system and in some cases surrounding myocardium in fetuses dying with CHB, provide in vivo support for several parallel lines of in vitro investigation."
The human tissue evidence that makes this the canonical account rather than one of two equals.
Direct antibody interference with cardiac calcium channels
direct_calcium_channel_blockade ALTERNATIVE
Evidence balance 2 support
A complementary account in which anti-Ro/La antibodies cross-react directly with cardiac L-type and T-type calcium channels, disturbing transmembrane calcium signalling in conduction tissue and impairing conduction without requiring inflammation. This is not a rival that would make the fibrosis account wrong: the two operate on different timescales, and a direct channel effect is the more natural explanation for the conduction abnormalities that are reversible, while fibrosis explains the ones that are not. It is recorded as ALTERNATIVE rather than modelled as its own node chain because no node in this entry currently rests on it, and inventing one would assert more than the cited sources do.
Show evidence (2 references)
PMID:22832822 SUPPORT Model Organism
"Evidence from animal models suggests that reactivity to the p200 region of the Ro52 protein, as well as antibody targeting of L-type calcium channels may be important in the development of cardiac neonatal lupus."
Names antibody targeting of L-type calcium channels as a candidate mechanism. Graded MODEL_ORGANISM because the review attributes it to animal models, which is also why it is ALTERNATIVE rather than CANONICAL - the fibrosis account has human tissue support and this one does not yet.
PMID:12402413 SUPPORT Human Clinical
"These antibodies may induce a myocarditis, or interact directly with calcium channel proteins with disturbance of transmembrane signaling at the level of the conduction tissue, or interfere with apoptosis."
States all three candidate routes side by side, including the direct calcium-channel interaction this hypothesis group names. The source's own "may" is why the group is ALTERNATIVE.
⚙

Pathophysiology

6
Maternal Anti-Ro/La IgG Transfer Across the Placenta
Maternal IgG autoantibodies against the Ro/SSA (Ro52/TRIM21 and Ro60) and La/SSB ribonucleoproteins, or against U1-RNP, cross the placenta and enter the fetal circulation. Because placental IgG transport rises through the second and third trimesters, fetal antibody concentration climbs across exactly the gestational window in which the conduction system is vulnerable. This node is the disease's sole initiating event; everything downstream is a consequence of antibody presence in fetal tissue.
Downstream
Surface Exposure of Ro/La Antigens on Apoptotic Fetal Cardiocytes
Antibody-Mediated Injury of Skin, Liver and Blood Cells
Show evidence (1 reference)
PMID:33470961 SUPPORT Human Clinical
"Neonatal lupus erythematosus is an autoimmune disease acquired during fetal life as a result of transplacental passage of maternal anti-Sjögren's-syndrome-related antigen A (anti-SSA/Ro), anti-Sjögren's-syndrome-related antigen B (anti-SSB/La) or anti-U1 ribonucleoprotein (anti-U1-RNP)..."
Names the three autoantibody specificities and states that transplacental passage is the acquisition mechanism, which is exactly what this node models.
Surface Exposure of Ro/La Antigens on Apoptotic Fetal Cardiocytes
Ro and La are normally intracellular ribonucleoproteins and are therefore invisible to circulating antibody. During the physiological apoptosis that accompanies remodelling of the developing atrioventricular conduction system, these antigens translocate to the surface of apoptotic cardiocytes, where the maternal antibodies can reach them. This developmentally timed unmasking is what confines cardiac injury to a narrow gestational window rather than occurring whenever antibody is present.
Diverted efferocytosis driving inflammatory fibrosis of the AV node
apoptotic fetal cardiocyte CL:0000746 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves apoptotic fetal cardiocyte, annotated with cardiac muscle cell (CL:0000746). CL:0000746 is a cell type from the Cell Ontology.
apoptotic process GO:0006915 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves apoptotic process (GO:0006915). GO:0006915 is a biological process from the Gene Ontology.
atrioventricular node UBERON:0002352 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in atrioventricular node (UBERON:0002352). UBERON:0002352 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Diverted Clearance of Opsonised Apoptotic Cardiocytes to Macrophages Diverted efferocytosis driving inflammatory fibrosis of the AV node
Show evidence (1 reference)
PMID:12139139 SUPPORT In Vitro
"Recent studies demonstrate that Ro/La ribonucleoproteins appear on the surface of apoptotic fetal cardiocytes and are recognized by their cognate antibodies, promoting an inflammatory response."
States the surface translocation of Ro/La on apoptotic fetal cardiocytes and their recognition by the cognate antibodies, which is the claim this node makes. Graded IN_VITRO because the sentence summarises cell-based studies of apoptotic cardiocytes.
Diverted Clearance of Opsonised Apoptotic Cardiocytes to Macrophages
Healthy cardiocytes normally phagocytose their apoptotic neighbours silently, a form of efferocytosis that produces no inflammation. Bound anti-Ro/La antibody blocks that uptake, so clearance is diverted to professional Fc-gamma-receptor-bearing phagocytes. The same apoptotic cell is then removed through an inflammatory route instead of a silent one. This diversion, rather than the antibody binding itself, is the step that converts a normal developmental process into tissue injury.
Diverted efferocytosis driving inflammatory fibrosis of the AV node
macrophage CL:0000235 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves macrophage (CL:0000235). CL:0000235 is a cell type from the Cell Ontology.
apoptotic cell clearance GO:0043277 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased apoptotic cell clearance (GO:0043277). GO:0043277 is a biological process from the Gene Ontology. ↓ DECREASED inflammatory response GO:0006954 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased inflammatory response (GO:0006954). GO:0006954 is a biological process from the Gene Ontology. ↑ INCREASED
Downstream
TGF-beta-Driven Fibrosis and Calcification of the Conduction System Diverted efferocytosis driving inflammatory fibrosis of the AV node
Show evidence (2 references)
PMID:18250129 SUPPORT In Vitro
"cardiocytes are capable of phagocytosing autologous apoptotic cardiocytes and anti-Ro/La antibodies inhibit this function"
The direct statement of this node's mechanism: cardiocyte-mediated clearance of apoptotic cardiocytes exists, and anti-Ro/La antibody inhibits it. Graded IN_VITRO because the phagocytosis assay is a cell-based experiment.
PMID:18250129 SUPPORT In Vitro
"Recognizing that this perturbation of physiologic efferocytosis might divert uptake to professional Fc gamma R-bearing phagocytes fits well with experiments demonstrating macrophage secretion of pro-inflammatory and fibrosing cytokines when coincubated with apoptotic cardiocytes bound by Ro/La..."
Supports the diversion of clearance to professional phagocytes and the resulting secretion of pro-inflammatory and pro-fibrotic cytokines, the link from this node to the fibrosis node downstream.
TGF-beta-Driven Fibrosis and Calcification of the Conduction System
Macrophages taking up antibody-bound apoptotic cardiocytes secrete pro-inflammatory and pro-fibrosing cytokines, and crosstalk with myofibroblasts drives TGF-beta expression, extensive fibrosis and dystrophic calcification within the atrioventricular node. Conduction tissue is replaced by scar. The claim that this is structural rather than inflammatory carries the entry's main clinical implication: once replacement is complete the lesion cannot be reversed by suppressing inflammation.
myofibroblast CL:0000186 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves myofibroblast, annotated with myofibroblast cell (CL:0000186). CL:0000186 is a cell type from the Cell Ontology.
transforming growth factor beta receptor signaling pathway GO:0007179 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased transforming growth factor beta receptor signaling pathway (GO:0007179). GO:0007179 is a biological process from the Gene Ontology. ↑ INCREASED
atrioventricular node UBERON:0002352 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in atrioventricular node (UBERON:0002352). UBERON:0002352 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Irreversible Complete Atrioventricular Block
Show evidence (1 reference)
PMID:18250129 SUPPORT Human Clinical
"The identification of exaggerated apoptosis, macrophage/myfibroblast crosstalk, TGF beta expression, and extensive fibrosis in the conducting system and in some cases surrounding myocardium in fetuses dying with CHB, provide in vivo support for several parallel lines of in vitro investigation."
Reports the macrophage-myofibroblast crosstalk, TGF-beta expression and conduction-system fibrosis this node models, observed in human fetal tissue rather than in a model system. Graded HUMAN_CLINICAL because the finding is from fetuses dying with congenital heart block.
Irreversible Complete Atrioventricular Block
Fibrous replacement of the atrioventricular node produces third-degree block: atrial and ventricular activity become fully dissociated and ventricular rate falls to a junctional or ventricular escape rhythm. Most survivors require permanent pacing. Injury may extend beyond the node to the myocardium and endocardium, which is the origin of the late dilated cardiomyopathy and endocardial fibroelastosis seen in some survivors whose in-utero ventricular function was normal.
Show evidence (2 references)
PMID:12139139 SUPPORT Human Clinical
"Established third-degree block appears to be irreversible."
The irreversibility claim that distinguishes this node from the transient manifestations, stated directly.
PMID:18250129 SUPPORT Human Clinical
"The spectrum of conduction abnormalities includes second and third-degree block, but injury can extend to the myocardium and endocardium, in rare cases without AV nodal dysfunction."
Supports both the conduction-block spectrum and the extension of injury beyond the node into myocardium and endocardium, which is what links this node to the cardiomyopathy phenotype.
Antibody-Mediated Injury of Skin, Liver and Blood Cells
In parallel with the cardiac lesion and by a separate, reversible route, maternal antibody produces annular photosensitive skin lesions, cholestatic or transaminitic liver involvement, and peripheral cytopenias. These manifestations share the cardiac trigger but not its outcome: no fibrotic replacement occurs, so all resolve as maternal IgG is catabolised over the first 6-12 months of life. Modelling them as a distinct node rather than as downstream of the cardiac chain is deliberate, since they occur in infants with entirely normal conduction.
keratinocyte CL:0000312 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves keratinocyte (CL:0000312). CL:0000312 is a cell type from the Cell Ontology.
Show evidence (1 reference)
PMID:33470961 SUPPORT Human Clinical
"Clinical manifestations include skin lesions, congenital heart block, hepatobiliary involvement and cytopenias. Most of the disorders disappear spontaneously after clearance of maternal antibodies. Cardiac symptoms, however, are not self-resolving and often pacemaker implantation is required."
Establishes both halves of the split this node encodes: the non-cardiac manifestations resolve on antibody clearance while the cardiac lesion does not.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Neonatal Lupus Erythematosus Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

11
Blood 3
Thrombocytopenia HP:0001873 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Thrombocytopenia (HP:0001873), qualified as temporality transient. HP:0001873 is a phenotype from the Human Phenotype Ontology.
Temporal: TRANSIENT
Show evidence (1 reference)
PMID:12402413 SUPPORT Human Clinical
"Skin lesions, haematological disorders, and hepatic cholestasis are other transient clinical features of the syndrome."
Supports the haematological manifestations being present and transient. Deliberately not the 15.5% source: that figure is for cytopenias as a group and belongs on the grouped node.
Decreased Neutrophil Count Decreased total neutrophil count HP:0001875 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Neutropenia, annotated with Decreased total neutrophil count (HP:0001875), qualified as temporality transient. HP:0001875 is a phenotype from the Human Phenotype Ontology.
Temporal: TRANSIENT
Show evidence (1 reference)
PMID:12402413 SUPPORT Human Clinical
"Skin lesions, haematological disorders, and hepatic cholestasis are other transient clinical features of the syndrome."
Groups the haematological manifestations with the other transient features, supporting both the occurrence and the transience.
Anemia HP:0001903 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Anemia (HP:0001903), qualified as temporality transient. HP:0001903 is a phenotype from the Human Phenotype Ontology.
Temporal: TRANSIENT
Show evidence (1 reference)
PMID:12402413 SUPPORT Human Clinical
"Skin lesions, haematological disorders, and hepatic cholestasis are other transient clinical features of the syndrome."
Supports the haematological manifestations as a transient feature. The abstract names haematological disorders collectively rather than anaemia specifically, which is why no frequency is attached here.
Cardiovascular 2
Dilated Cardiomyopathy HP:0001644 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Dilated cardiomyopathy (HP:0001644), qualified as course progressive. HP:0001644 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (1 reference)
PMID:22832822 SUPPORT Human Clinical
"Cardiac manifestations of neonatal lupus include anti-SSA/Ro-SSB/La-mediated conduction system disease and endocardial/myocardial damage resulting in cardiomyopathy."
States that cardiac neonatal lupus comprises both conduction disease and endocardial or myocardial damage producing cardiomyopathy.
Fetal Bradycardia HP:0001662 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Bradycardia (HP:0001662). HP:0001662 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:12139139 SUPPORT Human Clinical
"If fetal bradycardia is identified, a 2-dimensional and M-mode fetal echocardiographic and Doppler ultrasound should be obtained to determine whether there is an atrial arrhythmia or atrioventricular (AV) block"
Establishes fetal bradycardia as the presenting finding that triggers the diagnostic echocardiogram.
Digestive 1
Cholestatic Liver Involvement OCCASIONAL Cholestasis HP:0001396 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cholestasis (HP:0001396), qualified as temporality transient. HP:0001396 is a phenotype from the Human Phenotype Ontology.
Temporal: TRANSIENT
Show evidence (1 reference)
PMID:12402413 SUPPORT Human Clinical
"Skin lesions, haematological disorders, and hepatic cholestasis are other transient clinical features of the syndrome."
Names hepatic cholestasis directly as a transient feature of the syndrome.
Integument 1
Cutaneous Photosensitivity HP:0000992 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cutaneous photosensitivity (HP:0000992), qualified as temporality transient. HP:0000992 is a phenotype from the Human Phenotype Ontology.
Temporal: TRANSIENT
Show evidence (1 reference)
PMID:15234013 SUPPORT Human Clinical
"It has cutaneous manifestations similar to subacute cutaneous lupus erythematosus (SCLE)."
Graded PARTIAL deliberately, and the reason is worth stating. The quoted sentence establishes that the neonatal lupus rash resembles subacute cutaneous lupus erythematosus, which is the archetypal photosensitive lupus dermatosis; the photosensitivity of the neonatal lesions is an inference from that resemblance, not a claim this abstract makes directly. No abstract-level source stating it outright was found, so the inference is recorded openly rather than dressed up as a SUPPORT citation.
Other 4
Complete Congenital Heart Block FREQUENT Third degree atrioventricular block HP:0001709 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Third degree atrioventricular block (HP:0001709), qualified as course progressive. HP:0001709 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:31905489 SUPPORT Human Clinical
"The most frequently reported clinical manifestations of NLE were congenital heart block (CHB, 65.2%), cutaneous lupus (33.1%), and cytopenias (15.5%)."
Gives the frequency of congenital heart block across 755 individually reported cases. Note this is ascertainment-weighted rather than a true incidence: cardiac cases are far more likely to be published as case reports than skin-limited ones, which is why the entry records FREQUENT rather than treating 65.2% as the population figure.
PMID:12139139 SUPPORT Human Clinical
"CHB is most commonly diagnosed between 18 and 24 wk of gestation, and may be first, second or third degree (complete). Mortality approaches approximately 20%, and most surviving children require pacemakers."
Establishes the gestational detection window, the graded severity of the block, and the pacemaker requirement in survivors.
Annular Photosensitive Cutaneous Lesions FREQUENT Annular cutaneous lesion HP:0025528 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Annular photosensitive erythematous plaques, annotated with Annular cutaneous lesion (HP:0025528), qualified as temporality transient. HP:0025528 is a phenotype from the Human Phenotype Ontology.
Temporal: TRANSIENT
Show evidence (1 reference)
PMID:31905489 SUPPORT Human Clinical
"reports originating from Asia reported a higher prevalence of skin involvement (45.2%)"
Quantifies cutaneous involvement in the Asian-origin reports, the subgroup in which skin disease rather than heart block predominates.
Cytopenias OCCASIONAL Abnormality of blood and blood-forming tissues HP:0001871 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cytopenias, annotated with Abnormality of blood and blood-forming tissues (HP:0001871), qualified as temporality transient. HP:0001871 is a phenotype from the Human Phenotype Ontology.
Temporal: TRANSIENT
Show evidence (1 reference)
PMID:31905489 SUPPORT Human Clinical
"The most frequently reported clinical manifestations of NLE were congenital heart block (CHB, 65.2%), cutaneous lupus (33.1%), and cytopenias (15.5%)."
Records cytopenias in 15.5% of the 755 individually reported cases.
Endocardial Fibroelastosis HP:0001706 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Endocardial fibroelastosis (HP:0001706). HP:0001706 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:22832822 SUPPORT Human Clinical
"Cardiac manifestations of neonatal lupus include anti-SSA/Ro-SSB/La-mediated conduction system disease and endocardial/myocardial damage resulting in cardiomyopathy."
Names endocardial and myocardial damage as a cardiac manifestation distinct from conduction system disease.
🧬

Genetic Associations

3
TRIM21
Gene: TRIM21 hgnc:11312 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is TRIM21 (hgnc:11312). hgnc:11312 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: UNKNOWN
Show evidence (1 reference)
PMID:22832822 SUPPORT Model Organism
"Evidence from animal models suggests that reactivity to the p200 region of the Ro52 protein, as well as antibody targeting of L-type calcium channels may be important in the development of cardiac neonatal lupus."
Identifies the Ro52 p200 region as the epitope implicated in cardiac disease. Graded MODEL_ORGANISM because the review attributes the finding to animal models.
RO60
Gene: RO60 hgnc:11313 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is RO60 (hgnc:11313). hgnc:11313 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: UNKNOWN
Show evidence (1 reference)
PMID:12139139 SUPPORT In Vitro
"Recent studies demonstrate that Ro/La ribonucleoproteins appear on the surface of apoptotic fetal cardiocytes and are recognized by their cognate antibodies, promoting an inflammatory response."
Establishes the Ro ribonucleoproteins as the surface-exposed antigens recognised by maternal antibody. Note the source says Ro/La as a pair and does not resolve Ro60 from Ro52, so this supports Ro60 being an antigen rather than singling it out.
SSB
Gene: SSB hgnc:11316 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SSB (hgnc:11316). hgnc:11316 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: UNKNOWN
Show evidence (1 reference)
PMID:33470961 SUPPORT Human Clinical
"transplacental passage of maternal anti-Sjögren's-syndrome-related antigen A (anti-SSA/Ro), anti-Sjögren's-syndrome-related antigen B (anti-SSB/La) or anti-U1 ribonucleoprotein (anti-U1-RNP) antinuclear autoantibodies"
Names anti-SSB/La among the three pathogenic antibody specificities.
💊

Medical Actions

6
Maternal Fluorinated Corticosteroid Therapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: dexamethasone CHEBI:41879 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses dexamethasone (CHEBI:41879). CHEBI:41879 is a therapeutic agent from Chemical Entities of Biological Interest.
Fluorinated corticosteroids, principally dexamethasone, given to the mother so that active drug reaches the fetus. This is the therapy behind the entry's central asymmetry: it targets the inflammatory clearance step upstream of fibrosis, so it can act on block that is still evolving and cannot act on block that has already been replaced by scar. Modelled here because the entry states that conclusion in two places, and a conclusion about a therapy should name the therapy. Note the evidence is weak by design of the field rather than by omission - the source below describes only anecdotal and retrospective evidence with a trial then underway.
Mechanism Target:
Diverted Clearance of Opsonised Apoptotic Cardiocytes to Macrophages — Acts on the inflammatory clearance route, upstream of fibrotic replacement. This placement is what encodes why the therapy can help before the node fibroses and not after.
Show evidence (2 references)
PMID:12139139 SUPPORT Human Clinical
"To date, only anecdotal and retrospective evidence guides in utero therapy of CHB. A prospective trial is currently underway to evaluate the efficacy of maternal oral dexamethasone in treating newly identified first, second or third degree block."
Graded PARTIAL, and the grading is the point. The quoted sentence establishes that maternal dexamethasone is the therapy being evaluated, and in the same breath that the evidence for it was anecdotal and retrospective. Recording it as SUPPORT would overstate a treatment the source itself describes as unproven.
PMID:12139139 SUPPORT Human Clinical
"Established third-degree block appears to be irreversible."
The boundary on what this therapy can achieve, and the reason it is attached to the clearance node rather than to the block itself.
Sympathomimetic Therapy for Fetal Hydrops
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Sympathomimetic agents, used with dexamethasone, for the fetus that develops hydrops from the bradycardia. This treats the haemodynamic consequence of the block, not the immune lesion, which is why it carries no target_mechanisms link to the pathophysiology chain.
Show evidence (1 reference)
PMID:12139139 SUPPORT Human Clinical
"Dexamethasone and sympathomimetics may be of some benefit in treating hydrops fetalis."
Graded PARTIAL because the source says "may be of some benefit", which is a hedge the entry should carry rather than flatten.
Permanent Cardiac Pacing
Action: pacemaker placementNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is pacemaker placement (NCIT:C80434). NCIT:C80434 is a clinical intervention from the NCI Thesaurus. Ontology label: Pacemaker Placement NCIT:C80434
Pacemaker implantation is the definitive treatment for established complete block and is required by most survivors. It manages the consequence rather than the cause; no therapy restores conduction once the node is fibrosed.
Mechanism Target:
Irreversible Complete Atrioventricular Block — Restores an adequate ventricular rate downstream of the block. It does not act on the fibrotic lesion.
Show evidence (1 reference)
PMID:33470961 SUPPORT Human Clinical
"Cardiac symptoms, however, are not self-resolving and often pacemaker implantation is required."
States both the non-resolution of cardiac disease and the pacemaker requirement that follows from it.
Maternal Hydroxychloroquine Prophylaxis
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: hydroxychloroquine CHEBI:5801 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses hydroxychloroquine (CHEBI:5801). CHEBI:5801 is a therapeutic agent from Chemical Entities of Biological Interest.
Hydroxychloroquine given to an antibody-positive mother, ideally from early pregnancy, is the principal preventive strategy in mothers with a previously affected child. It is prophylaxis against the fibrotic lesion forming, not a treatment for established block.
Mechanism Target:
Diverted Clearance of Opsonised Apoptotic Cardiocytes to Macrophages — Acts upstream of fibrosis, on the inflammatory clearance route, which is consistent with its being effective only as prevention.
Show evidence (1 reference)
PMID:33470961 SUPPORT Human Clinical
"Testing for antinuclear antibodies should be considered in every pregnant woman since early treatment with hydroxychloroquine or intravenous immunoglobulin (IVIG) has proven to be effective in preventing congenital heart block."
States the preventive efficacy of early hydroxychloroquine against congenital heart block, and the word "preventing" is what licenses modelling this as prophylaxis rather than treatment.
Intravenous Immunoglobulin
Action: intravenous immunoglobulin therapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is intravenous immunoglobulin therapy (NCIT:C121331). NCIT:C121331 is a clinical intervention from the NCI Thesaurus. Ontology label: Intravenous Immunoglobulin Therapy NCIT:C121331
IVIG has been used both preventively in at-risk pregnancies and as an adjunct in established disease. The evidence base is weaker than for hydroxychloroquine and dedicated trials have been largely negative for prevention of recurrence at the doses studied.
Show evidence (1 reference)
PMID:33470961 SUPPORT Human Clinical
"early treatment with hydroxychloroquine or intravenous immunoglobulin (IVIG) has proven to be effective in preventing congenital heart block"
Graded PARTIAL rather than SUPPORT. The guideline groups IVIG with hydroxychloroquine, but the trial evidence for the two is not equivalent, so quoting this sentence as unqualified support for IVIG would overstate what is established.
Sun Avoidance for Cutaneous Disease
Action: supportive careNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is supportive care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. Ontology label: Supportive Care NCIT:C15747
Because the rash is photo-provoked and self-limited, management of skin-limited neonatal lupus is protective rather than pharmacological.
Mechanism Target:
Antibody-Mediated Injury of Skin, Liver and Blood Cells — Removes the ultraviolet co-factor while maternal antibody clears.
Show evidence (1 reference)
PMID:15234013 SUPPORT Human Clinical
"The cutaneous, hematologic, and hepatic abnormalities are transient, clearing by 6 months of age."
Establishes that the non-cardiac manifestations are self-limited, which is the rationale for managing them supportively rather than with immunosuppression.
🌍

Environmental Factors

1
Ultraviolet light exposure
exposure to ultraviolet radiation ECTO:0000006 Environmental Conditions, Treatments and Exposures Ontology (ECTO) Relation: this environmental factor is this exposure This environmental factor is exposure to ultraviolet radiation (ECTO:0000006). ECTO:0000006 is an exposure from the Environmental Conditions, Treatments and Exposures Ontology.
Ultraviolet exposure is the recognised exacerbating factor for the cutaneous arm. It is not a cause of the disease - the maternal antibody is - but it is what makes the rash photo-distributed and what sun avoidance is avoiding, so it is modelled as a first-class exposure rather than left implicit in a treatment rationale.
Show evidence (1 reference)
PMID:15234013 SUPPORT Human Clinical
"It has cutaneous manifestations similar to subacute cutaneous lupus erythematosus (SCLE)."
Entry-level evidence for treating ultraviolet light as a relevant exposure in this disease. Graded PARTIAL deliberately: the abstract establishes the resemblance to SCLE, the archetypal photosensitive lupus dermatosis, and the ultraviolet role is inferred from that rather than stated. No abstract-level source asserting it outright was found, and this entry would rather show the inference than dress it up.
Mechanism Target:
EXACERBATES Antibody-Mediated Injury of Skin, Liver and Blood Cells — Ultraviolet exposure aggravates the antibody-mediated cutaneous injury. Attached to the transient arm only: there is no evidence that light exposure influences the cardiac lesion, which forms in utero.
Show evidence (1 reference)
PMID:15234013 SUPPORT Human Clinical
"It has cutaneous manifestations similar to subacute cutaneous lupus erythematosus (SCLE)."
Graded PARTIAL for the same reason as the photosensitivity phenotype: the resemblance to SCLE, the archetypal photosensitive lupus dermatosis, is what the abstract states, and the UV-exacerbation link is an inference from it rather than a claim this source makes directly. Recorded openly rather than over-graded.
🔬

Diagnosis

2
Maternal Anti-Ro/SSA and Anti-La/SSB Serology
Detection of maternal anti-Ro/SSA and anti-La/SSB antibodies is the test that establishes the diagnosis, in the infant's mother rather than in the infant. Because about half of mothers are asymptomatic, a negative maternal history does not exclude it.
Show evidence (1 reference)
PMID:12139139 SUPPORT Human Clinical
"The mother's serum should be tested by ELISA for anti-Ro and/or anti-La antibodies."
States the confirmatory serological test and that the specimen is maternal.
Serial Fetal Echocardiography with Mechanical PR Interval
Serial fetal echocardiography from around 16 weeks, measuring the Doppler-derived mechanical PR interval, is the surveillance strategy for antibody-positive pregnancies. Its purpose is to catch first-degree block while it may still be reversible, since complete block is not.
Show evidence (2 references)
PMID:12139139 SUPPORT Human Clinical
"Serial echocardiographic monitoring of high-risk pregnancies, using the mechanical PR interval to identify first degree block, may afford the earliest opportunities for therapeutic intervention."
Describes the surveillance modality and the interval measured, and states the rationale of catching block early enough to intervene.
PMID:12402413 SUPPORT Human Clinical
"Serial echocardiograms and obstetric sonograms, performed at least every 2 wk starting from the 16 wk gestation, are recommended in anti-Ro/SSA positive pregnant women."
Gives the surveillance interval and starting gestational age.
📈

Progression

1
Transient manifestations resolving with maternal antibody clearance
The cutaneous, hepatic and haematological manifestations clear by about 6 months of age, tracking the catabolism of maternal IgG. This is the diagnostic signature of a passively acquired disease and the reason these features need no immunosuppression.
Show evidence (1 reference)
PMID:15234013 SUPPORT Human Clinical
"The cutaneous, hematologic, and hepatic abnormalities are transient, clearing by 6 months of age. However, CHB is permanent and requires a pacemaker in many cases."
States the resolution timeline for the transient manifestations and contrasts it with the permanence of heart block, which is the whole two-halves structure of this entry.
📊

Prevalence

1
Pregnancies of anti-Ro/SSA-positive women with known connective tissue disease
Point Prevalence 2000.0 per 100,000 >1 in 1,000
Prevalence of complete congenital heart block specifically, not of all neonatal lupus manifestations. Recorded as 2% of at-risk pregnancies.
Show evidence (1 reference)
PMID:12402413 SUPPORT Human Clinical
"The prevalence of complete CHB in newborns of anti-Ro/SSA positive women and with known connective-tissue disease was 2%."
The cited figure is explicitly a prevalence of complete block within the at-risk antibody-positive population, which is the denominator recorded in this record.
{ }

Source YAML

click to show 
name: Neonatal Lupus Erythematosus
creation_date: "2026-08-27T23:30:00Z"
category: Autoimmune
description: >-
  Neonatal lupus erythematosus is a passively acquired autoimmune disease of the
  fetus and newborn caused by transplacental transfer of maternal IgG
  autoantibodies against the Ro/SSA and La/SSB ribonucleoproteins, and in a
  distinct subset against U1-RNP. Despite the name it is not systemic lupus
  erythematosus occurring in an infant: the affected child has no autoimmune
  disease of its own, produces no autoantibody, and recovers as maternal IgG is
  catabolised. Roughly half of the mothers are asymptomatic at delivery and are
  identified only by the birth of an affected child, so maternal lupus is not a
  prerequisite. The disease separates cleanly into two mechanistic halves that
  share one trigger. The transient half, comprising annular photosensitive skin
  lesions, cholestatic hepatitis and cytopenias, resolves over 6-12 months as
  antibody clears. The permanent half is cardiac: between 18 and 26 weeks of
  gestation, physiological remodelling of the developing atrioventricular
  conduction system exposes normally intracellular Ro and La antigens on the
  surface of apoptotic cardiocytes, maternal antibody binding diverts their
  clearance from neighbouring cardiocytes to professional phagocytes, and the
  resulting macrophage-myofibroblast crosstalk and TGF-beta-driven fibrosis
  replace conduction tissue irreversibly. This is why anti-inflammatory therapy
  can sometimes reverse incomplete block but never reverses established
  third-degree block, and it is what makes the disease a widely used model for
  studying how an autoantibody alone causes end-organ injury.
parents:
  - Autoimmune Disease
  - Cardiac Conduction Disorder
synonyms:
  - neonatal lupus syndrome
  - NLE
  - NLS
  - congenital heart block associated with maternal anti-Ro/SSA antibodies
disease_term:
  preferred_term: neonatal lupus erythematosus
  term:
    id: MONDO:0018360
    label: neonatal lupus erythematosus
notes: >-
  Relationship to the Systemic Lupus Erythematosus entry. kb/disorders/Systemic_Lupus_Erythematosus.yaml
  carries a has_subtypes entry named "Neonatal Lupus" with a one-line description and
  no MONDO binding. That entry is retained as a pointer; this file is the curated
  disease. The two are deliberately not modelled as parent and subtype, because
  neonatal lupus is not a form of SLE: the pathogenic agent is maternal IgG acting
  on fetal tissue, the affected individual has no autoimmunity, and roughly half of
  the mothers have no lupus at all. MONDO models MONDO:0018360 as its own disease
  term rather than as a child of MONDO:0007915 (systemic lupus erythematosus).
inheritance:
  - name: Not inherited (passively acquired)
    description: >-
      Neonatal lupus is not transmitted as a Mendelian trait. The determinant of
      risk is the mother's antibody status, which is why recurrence in a
      subsequent pregnancy is high (of the order of 15-20% after an affected
      child) while the general population risk is negligible. That recurrence
      figure is often misread as a segregation ratio; it is not one, and no
      inheritance_term is bound here because the HPO mode-of-inheritance subtree
      has no value that correctly describes maternal-antibody transmission.
    evidence:
      - reference: PMID:12139139
        reference_title: "Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          CHB occurs in approximately 1-5% of pregnancies in mothers with
          anti-Ro/La antibodies, independent of the mother's disease status, and
          in approximately 15-20% of pregnancies following the birth of a child
          with NLS.
        explanation: >-
          States both the baseline per-pregnancy risk in antibody-positive
          mothers and the recurrence risk after an affected child, and makes
          explicit that risk tracks antibody status rather than maternal disease.
prevalence:
  - population: Pregnancies of anti-Ro/SSA-positive women with known connective tissue disease
    measure_type: POINT_PREVALENCE
    prevalence_class: ABOVE_1_IN_1000
    rate_per_100000: 2000.0
    notes: >-
      Prevalence of complete congenital heart block specifically, not of all
      neonatal lupus manifestations. Recorded as 2% of at-risk pregnancies.
    evidence:
      - reference: PMID:12402413
        reference_title: "Neonatal lupus."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The prevalence of complete CHB in newborns of anti-Ro/SSA positive
          women and with known connective-tissue disease was 2%.
        explanation: >-
          The cited figure is explicitly a prevalence of complete block within
          the at-risk antibody-positive population, which is the denominator
          recorded in this record.
mechanistic_hypotheses:
  - hypothesis_group_id: apoptosis_efferocytosis_fibrosis
    hypothesis_label: Diverted efferocytosis driving inflammatory fibrosis of the AV node
    status: CANONICAL
    description: >-
      The mechanism this entry models in full. Maternal antibody bound to
      surface-exposed Ro/La on apoptotic cardiocytes blocks their silent
      clearance by neighbouring cardiocytes, diverting uptake to
      Fc-gamma-receptor-bearing macrophages, whose pro-inflammatory and
      pro-fibrotic secretion drives TGF-beta-mediated fibrosis and permanent
      replacement of conduction tissue. It is treated as canonical because it is
      the account with direct human tissue support: fibrosis, TGF-beta
      expression and macrophage-myofibroblast crosstalk have been observed in
      fetuses dying with congenital heart block.
    evidence:
      - reference: PMID:18250129
        reference_title: >-
          Dying right to live longer: positing apoptosis as a link between
          maternal autoantibodies and congenital heart block.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The identification of exaggerated apoptosis, macrophage/myfibroblast
          crosstalk, TGF beta expression, and extensive fibrosis in the
          conducting system and in some cases surrounding myocardium in fetuses
          dying with CHB, provide in vivo support for several parallel lines of
          in vitro investigation.
        explanation: >-
          The human tissue evidence that makes this the canonical account rather
          than one of two equals.
  - hypothesis_group_id: direct_calcium_channel_blockade
    hypothesis_label: Direct antibody interference with cardiac calcium channels
    status: ALTERNATIVE
    description: >-
      A complementary account in which anti-Ro/La antibodies cross-react
      directly with cardiac L-type and T-type calcium channels, disturbing
      transmembrane calcium signalling in conduction tissue and impairing
      conduction without requiring inflammation. This is not a rival that would
      make the fibrosis account wrong: the two operate on different timescales,
      and a direct channel effect is the more natural explanation for the
      conduction abnormalities that are reversible, while fibrosis explains the
      ones that are not. It is recorded as ALTERNATIVE rather than modelled as
      its own node chain because no node in this entry currently rests on it,
      and inventing one would assert more than the cited sources do.
    evidence:
      - reference: PMID:22832822
        reference_title: >-
          Neonatal lupus: advances in understanding pathogenesis and identifying
          treatments of cardiac disease.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Evidence from animal models suggests that reactivity to the p200
          region of the Ro52 protein, as well as antibody targeting of L-type
          calcium channels may be important in the development of cardiac
          neonatal lupus.
        explanation: >-
          Names antibody targeting of L-type calcium channels as a candidate
          mechanism. Graded MODEL_ORGANISM because the review attributes it to
          animal models, which is also why it is ALTERNATIVE rather than
          CANONICAL - the fibrosis account has human tissue support and this one
          does not yet.
      - reference: PMID:12402413
        reference_title: "Neonatal lupus."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          These antibodies may induce a myocarditis, or interact directly with
          calcium channel proteins with disturbance of transmembrane signaling
          at the level of the conduction tissue, or interfere with apoptosis.
        explanation: >-
          States all three candidate routes side by side, including the direct
          calcium-channel interaction this hypothesis group names. The source's
          own "may" is why the group is ALTERNATIVE.
pathophysiology:
  - name: Maternal Anti-Ro/La IgG Transfer Across the Placenta
    biological_scale: ORGANISM
    description: >-
      Maternal IgG autoantibodies against the Ro/SSA (Ro52/TRIM21 and Ro60) and
      La/SSB ribonucleoproteins, or against U1-RNP, cross the placenta and enter
      the fetal circulation. Because placental IgG transport rises through the
      second and third trimesters, fetal antibody concentration climbs across
      exactly the gestational window in which the conduction system is
      vulnerable. This node is the disease's sole initiating event; everything
      downstream is a consequence of antibody presence in fetal tissue.
    downstream:
      - target: Surface Exposure of Ro/La Antigens on Apoptotic Fetal Cardiocytes
      - target: Antibody-Mediated Injury of Skin, Liver and Blood Cells
    evidence:
      - reference: PMID:33470961
        reference_title: "Neonatal lupus erythematosus - practical guidelines."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Neonatal lupus erythematosus is an autoimmune disease acquired during
          fetal life as a result of transplacental passage of maternal
          anti-Sjögren's-syndrome-related antigen A (anti-SSA/Ro),
          anti-Sjögren's-syndrome-related antigen B (anti-SSB/La) or anti-U1
          ribonucleoprotein (anti-U1-RNP) antinuclear autoantibodies.
        explanation: >-
          Names the three autoantibody specificities and states that
          transplacental passage is the acquisition mechanism, which is exactly
          what this node models.
  - name: Surface Exposure of Ro/La Antigens on Apoptotic Fetal Cardiocytes
    biological_scale: CELLULAR
    description: >-
      Ro and La are normally intracellular ribonucleoproteins and are therefore
      invisible to circulating antibody. During the physiological apoptosis that
      accompanies remodelling of the developing atrioventricular conduction
      system, these antigens translocate to the surface of apoptotic
      cardiocytes, where the maternal antibodies can reach them. This
      developmentally timed unmasking is what confines cardiac injury to a
      narrow gestational window rather than occurring whenever antibody is
      present.
    cell_types:
      - preferred_term: apoptotic fetal cardiocyte
        term:
          id: CL:0000746
          label: cardiac muscle cell
    biological_processes:
      - preferred_term: apoptotic process
        term:
          id: GO:0006915
          label: apoptotic process
    locations:
      - preferred_term: atrioventricular node
        term:
          id: UBERON:0002352
          label: atrioventricular node
    downstream:
      - target: Diverted Clearance of Opsonised Apoptotic Cardiocytes to Macrophages
        hypothesis_groups:
          - apoptosis_efferocytosis_fibrosis
    evidence:
      - reference: PMID:12139139
        reference_title: "Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Recent studies demonstrate that Ro/La ribonucleoproteins appear on the
          surface of apoptotic fetal cardiocytes and are recognized by their
          cognate antibodies, promoting an inflammatory response.
        explanation: >-
          States the surface translocation of Ro/La on apoptotic fetal
          cardiocytes and their recognition by the cognate antibodies, which is
          the claim this node makes. Graded IN_VITRO because the sentence
          summarises cell-based studies of apoptotic cardiocytes.
  - name: Diverted Clearance of Opsonised Apoptotic Cardiocytes to Macrophages
    biological_scale: CELLULAR
    description: >-
      Healthy cardiocytes normally phagocytose their apoptotic neighbours
      silently, a form of efferocytosis that produces no inflammation. Bound
      anti-Ro/La antibody blocks that uptake, so clearance is diverted to
      professional Fc-gamma-receptor-bearing phagocytes. The same apoptotic cell
      is then removed through an inflammatory route instead of a silent one.
      This diversion, rather than the antibody binding itself, is the step that
      converts a normal developmental process into tissue injury.
    cell_types:
      - preferred_term: macrophage
        term:
          id: CL:0000235
          label: macrophage
    biological_processes:
      - preferred_term: apoptotic cell clearance
        term:
          id: GO:0043277
          label: apoptotic cell clearance
        modifier: DECREASED
      - preferred_term: inflammatory response
        term:
          id: GO:0006954
          label: inflammatory response
        modifier: INCREASED
    downstream:
      - target: TGF-beta-Driven Fibrosis and Calcification of the Conduction System
        hypothesis_groups:
          - apoptosis_efferocytosis_fibrosis
    evidence:
      - reference: PMID:18250129
        reference_title: >-
          Dying right to live longer: positing apoptosis as a link between
          maternal autoantibodies and congenital heart block.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          cardiocytes are capable of phagocytosing autologous apoptotic
          cardiocytes and anti-Ro/La antibodies inhibit this function
        explanation: >-
          The direct statement of this node's mechanism: cardiocyte-mediated
          clearance of apoptotic cardiocytes exists, and anti-Ro/La antibody
          inhibits it. Graded IN_VITRO because the phagocytosis assay is a
          cell-based experiment.
      - reference: PMID:18250129
        reference_title: >-
          Dying right to live longer: positing apoptosis as a link between
          maternal autoantibodies and congenital heart block.
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Recognizing that this perturbation of physiologic efferocytosis might
          divert uptake to professional Fc gamma R-bearing phagocytes fits well
          with experiments demonstrating macrophage secretion of
          pro-inflammatory and fibrosing cytokines when coincubated with
          apoptotic cardiocytes bound by Ro/La antibodies.
        explanation: >-
          Supports the diversion of clearance to professional phagocytes and the
          resulting secretion of pro-inflammatory and pro-fibrotic cytokines,
          the link from this node to the fibrosis node downstream.
  - name: TGF-beta-Driven Fibrosis and Calcification of the Conduction System
    biological_scale: TISSUE
    description: >-
      Macrophages taking up antibody-bound apoptotic cardiocytes secrete
      pro-inflammatory and pro-fibrosing cytokines, and crosstalk with
      myofibroblasts drives TGF-beta expression, extensive fibrosis and
      dystrophic calcification within the atrioventricular node. Conduction
      tissue is replaced by scar. The claim that this is structural rather than
      inflammatory carries the entry's main clinical implication: once
      replacement is complete the lesion cannot be reversed by suppressing
      inflammation.
    cell_types:
      - preferred_term: myofibroblast
        term:
          id: CL:0000186
          label: myofibroblast cell
    biological_processes:
      - preferred_term: transforming growth factor beta receptor signaling pathway
        term:
          id: GO:0007179
          label: transforming growth factor beta receptor signaling pathway
        modifier: INCREASED
    locations:
      - preferred_term: atrioventricular node
        term:
          id: UBERON:0002352
          label: atrioventricular node
    downstream:
      - target: Irreversible Complete Atrioventricular Block
    evidence:
      - reference: PMID:18250129
        reference_title: >-
          Dying right to live longer: positing apoptosis as a link between
          maternal autoantibodies and congenital heart block.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The identification of exaggerated apoptosis, macrophage/myfibroblast
          crosstalk, TGF beta expression, and extensive fibrosis in the
          conducting system and in some cases surrounding myocardium in fetuses
          dying with CHB, provide in vivo support for several parallel lines of
          in vitro investigation.
        explanation: >-
          Reports the macrophage-myofibroblast crosstalk, TGF-beta expression
          and conduction-system fibrosis this node models, observed in human
          fetal tissue rather than in a model system. Graded HUMAN_CLINICAL
          because the finding is from fetuses dying with congenital heart block.
  - name: Irreversible Complete Atrioventricular Block
    biological_scale: ORGANISM
    description: >-
      Fibrous replacement of the atrioventricular node produces third-degree
      block: atrial and ventricular activity become fully dissociated and
      ventricular rate falls to a junctional or ventricular escape rhythm. Most
      survivors require permanent pacing. Injury may extend beyond the node to
      the myocardium and endocardium, which is the origin of the late dilated
      cardiomyopathy and endocardial fibroelastosis seen in some survivors whose
      in-utero ventricular function was normal.
    evidence:
      - reference: PMID:12139139
        reference_title: "Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Established third-degree block appears to be irreversible.
        explanation: >-
          The irreversibility claim that distinguishes this node from the
          transient manifestations, stated directly.
      - reference: PMID:18250129
        reference_title: >-
          Dying right to live longer: positing apoptosis as a link between
          maternal autoantibodies and congenital heart block.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The spectrum of conduction abnormalities includes second and
          third-degree block, but injury can extend to the myocardium and
          endocardium, in rare cases without AV nodal dysfunction.
        explanation: >-
          Supports both the conduction-block spectrum and the extension of
          injury beyond the node into myocardium and endocardium, which is what
          links this node to the cardiomyopathy phenotype.
  - name: Antibody-Mediated Injury of Skin, Liver and Blood Cells
    biological_scale: ORGANISM
    description: >-
      In parallel with the cardiac lesion and by a separate, reversible route,
      maternal antibody produces annular photosensitive skin lesions, cholestatic
      or transaminitic liver involvement, and peripheral cytopenias. These
      manifestations share the cardiac trigger but not its outcome: no fibrotic
      replacement occurs, so all resolve as maternal IgG is catabolised over the
      first 6-12 months of life. Modelling them as a distinct node rather than as
      downstream of the cardiac chain is deliberate, since they occur in infants
      with entirely normal conduction.
    cell_types:
      - preferred_term: keratinocyte
        term:
          id: CL:0000312
          label: keratinocyte
    evidence:
      - reference: PMID:33470961
        reference_title: "Neonatal lupus erythematosus - practical guidelines."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Clinical manifestations include skin lesions, congenital heart block,
          hepatobiliary involvement and cytopenias. Most of the disorders
          disappear spontaneously after clearance of maternal antibodies.
          Cardiac symptoms, however, are not self-resolving and often pacemaker
          implantation is required.
        explanation: >-
          Establishes both halves of the split this node encodes: the
          non-cardiac manifestations resolve on antibody clearance while the
          cardiac lesion does not.
phenotypes:
  - name: Complete Congenital Heart Block
    category: Cardiovascular
    description: >-
      Third-degree atrioventricular block, the defining and only permanent
      manifestation. Most commonly detected between 18 and 26 weeks of
      gestation, on surveillance echocardiography or after fetal bradycardia is
      noticed.
    phenotype_term:
      preferred_term: Third degree atrioventricular block
      term:
        id: HP:0001709
        label: Third degree atrioventricular block
      clinical_course: PROGRESSIVE
    frequency: FREQUENT
    evidence:
      - reference: PMID:31905489
        reference_title: >-
          Geoepidemiology and clinical characteristics of neonatal lupus
          erythematosus: a systematic literature review of individual patients'
          data.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The most frequently reported clinical manifestations of NLE were
          congenital heart block (CHB, 65.2%), cutaneous lupus (33.1%), and
          cytopenias (15.5%).
        explanation: >-
          Gives the frequency of congenital heart block across 755 individually
          reported cases. Note this is ascertainment-weighted rather than a true
          incidence: cardiac cases are far more likely to be published as case
          reports than skin-limited ones, which is why the entry records
          FREQUENT rather than treating 65.2% as the population figure.
      - reference: PMID:12139139
        reference_title: "Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          CHB is most commonly diagnosed between 18 and 24 wk of gestation, and
          may be first, second or third degree (complete). Mortality approaches
          approximately 20%, and most surviving children require pacemakers.
        explanation: >-
          Establishes the gestational detection window, the graded severity of
          the block, and the pacemaker requirement in survivors.
  - name: Annular Photosensitive Cutaneous Lesions
    category: Dermatologic
    description: >-
      Erythematous annular or polycyclic plaques, classically periorbital and on
      the scalp and face, often photo-distributed and appearing or worsening
      after light exposure. Present at birth or emerging over the first weeks.
      Resolves without scarring in most infants, occasionally leaving
      telangiectasia or dyspigmentation.
    phenotype_term:
      preferred_term: Annular photosensitive erythematous plaques
      term:
        id: HP:0025528
        label: Annular cutaneous lesion
      temporality: TRANSIENT
    frequency: FREQUENT
    evidence:
      - reference: PMID:31905489
        reference_title: >-
          Geoepidemiology and clinical characteristics of neonatal lupus
          erythematosus: a systematic literature review of individual patients'
          data.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          reports originating from Asia reported a higher prevalence of skin
          involvement (45.2%)
        explanation: >-
          Quantifies cutaneous involvement in the Asian-origin reports, the
          subgroup in which skin disease rather than heart block predominates.
  - name: Cutaneous Photosensitivity
    category: Dermatologic
    description: >-
      The cutaneous lesions are characteristically provoked or aggravated by
      ultraviolet exposure, which is why sun avoidance is the principal
      management measure for skin-limited disease.
    phenotype_term:
      preferred_term: Cutaneous photosensitivity
      term:
        id: HP:0000992
        label: Cutaneous photosensitivity
      temporality: TRANSIENT
    evidence:
      - reference: PMID:15234013
        reference_title: "Neonatal lupus erythematosus."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          It has cutaneous manifestations similar to subacute cutaneous lupus
          erythematosus (SCLE).
        explanation: >-
          Graded PARTIAL deliberately, and the reason is worth stating. The
          quoted sentence establishes that the neonatal lupus rash resembles
          subacute cutaneous lupus erythematosus, which is the archetypal
          photosensitive lupus dermatosis; the photosensitivity of the neonatal
          lesions is an inference from that resemblance, not a claim this
          abstract makes directly. No abstract-level source stating it outright
          was found, so the inference is recorded openly rather than dressed up
          as a SUPPORT citation.
  - name: Thrombocytopenia
    category: Hematologic
    description: >-
      Antibody-mediated peripheral destruction of fetal platelets. Transient,
      resolving with maternal antibody clearance. No thrombocytopenia-specific
      frequency is recorded: the 15.5% figure available from the systematic
      review is for cytopenias as a group, and is carried on the grouped
      Cytopenias phenotype rather than attached to this narrower term.
    phenotype_term:
      preferred_term: Thrombocytopenia
      term:
        id: HP:0001873
        label: Thrombocytopenia
      temporality: TRANSIENT
    evidence:
      - reference: PMID:12402413
        reference_title: "Neonatal lupus."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Skin lesions, haematological disorders, and hepatic cholestasis are
          other transient clinical features of the syndrome.
        explanation: >-
          Supports the haematological manifestations being present and
          transient. Deliberately not the 15.5% source: that figure is for
          cytopenias as a group and belongs on the grouped node.
  - name: Cytopenias
    category: Hematologic
    description: >-
      The grouped haematological phenotype - thrombocytopenia, decreased
      neutrophil count and anaemia together - attributed to antibody-mediated
      peripheral destruction of fetal blood cells. This node exists to carry the
      group-level frequency, which is the only frequency the literature reports;
      the individual cytopenias are modelled separately and deliberately carry
      no frequency of their own.
    phenotype_term:
      preferred_term: Cytopenias
      term:
        id: HP:0001871
        label: Abnormality of blood and blood-forming tissues
      temporality: TRANSIENT
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:31905489
        reference_title: >-
          Geoepidemiology and clinical characteristics of neonatal lupus
          erythematosus: a systematic literature review of individual patients'
          data.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The most frequently reported clinical manifestations of NLE were
          congenital heart block (CHB, 65.2%), cutaneous lupus (33.1%), and
          cytopenias (15.5%).
        explanation: >-
          Records cytopenias in 15.5% of the 755 individually reported cases.
  - name: Decreased Neutrophil Count
    category: Hematologic
    description: >-
      Neutropenia is the most commonly reported of the neonatal lupus
      cytopenias. Usually asymptomatic and self-limited.
    phenotype_term:
      preferred_term: Neutropenia
      term:
        id: HP:0001875
        label: Decreased total neutrophil count
      temporality: TRANSIENT
    evidence:
      - reference: PMID:12402413
        reference_title: "Neonatal lupus."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Skin lesions, haematological disorders, and hepatic cholestasis are
          other transient clinical features of the syndrome.
        explanation: >-
          Groups the haematological manifestations with the other transient
          features, supporting both the occurrence and the transience.
  - name: Anemia
    category: Hematologic
    description: >-
      Haemolytic or non-haemolytic anaemia from antibody-mediated destruction of
      fetal red cells. Named in the disease description and in the grouped
      Cytopenias node; modelled here so it is not the one cytopenia present only
      in prose. No individual frequency is available.
    phenotype_term:
      preferred_term: Anemia
      term:
        id: HP:0001903
        label: Anemia
      temporality: TRANSIENT
    evidence:
      - reference: PMID:12402413
        reference_title: "Neonatal lupus."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Skin lesions, haematological disorders, and hepatic cholestasis are
          other transient clinical features of the syndrome.
        explanation: >-
          Supports the haematological manifestations as a transient feature.
          The abstract names haematological disorders collectively rather than
          anaemia specifically, which is why no frequency is attached here.
  - name: Endocardial Fibroelastosis
    category: Cardiovascular
    description: >-
      Endocardial and myocardial injury extending beyond the conduction system.
      Described in the pathophysiology as the origin of late cardiomyopathy in
      survivors; modelled here so it is a phenotype rather than only prose.
    phenotype_term:
      preferred_term: Endocardial fibroelastosis
      term:
        id: HP:0001706
        label: Endocardial fibroelastosis
    evidence:
      - reference: PMID:22832822
        reference_title: >-
          Neonatal lupus: advances in understanding pathogenesis and identifying
          treatments of cardiac disease.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Cardiac manifestations of neonatal lupus include anti-SSA/Ro-SSB/La-mediated
          conduction system disease and endocardial/myocardial damage resulting in
          cardiomyopathy.
        explanation: >-
          Names endocardial and myocardial damage as a cardiac manifestation
          distinct from conduction system disease.
  - name: Cholestatic Liver Involvement
    category: Hepatic
    description: >-
      Cholestasis, transaminase elevation and hepatomegaly, present at birth or
      developing over the first weeks. Almost always transient; rare severe
      cases with liver failure have been reported.
    phenotype_term:
      preferred_term: Cholestasis
      term:
        id: HP:0001396
        label: Cholestasis
      temporality: TRANSIENT
    frequency: OCCASIONAL
    evidence:
      - reference: PMID:12402413
        reference_title: "Neonatal lupus."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Skin lesions, haematological disorders, and hepatic cholestasis are
          other transient clinical features of the syndrome.
        explanation: >-
          Names hepatic cholestasis directly as a transient feature of the
          syndrome.
  - name: Dilated Cardiomyopathy
    category: Cardiovascular
    description: >-
      A minority of infants with cardiac neonatal lupus develop cardiomyopathy,
      sometimes after normal in-utero ventricular function, reflecting antibody
      injury extending beyond the conduction system into myocardium and
      endocardium.
    phenotype_term:
      preferred_term: Dilated cardiomyopathy
      term:
        id: HP:0001644
        label: Dilated cardiomyopathy
      clinical_course: PROGRESSIVE
    evidence:
      - reference: PMID:22832822
        reference_title: >-
          Neonatal lupus: advances in understanding pathogenesis and identifying
          treatments of cardiac disease.
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Cardiac manifestations of neonatal lupus include anti-SSA/Ro-SSB/La-mediated
          conduction system disease and endocardial/myocardial damage resulting in
          cardiomyopathy.
        explanation: >-
          States that cardiac neonatal lupus comprises both conduction disease
          and endocardial or myocardial damage producing cardiomyopathy.
  - name: Fetal Bradycardia
    category: Cardiovascular
    description: >-
      The usual presenting sign. A fetal heart rate in the 50-80 bpm range on
      routine obstetric auscultation or ultrasound is what prompts the
      echocardiogram that establishes the diagnosis.
    phenotype_term:
      preferred_term: Bradycardia
      term:
        id: HP:0001662
        label: Bradycardia
    evidence:
      - reference: PMID:12139139
        reference_title: "Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          If fetal bradycardia is identified, a 2-dimensional and M-mode fetal
          echocardiographic and Doppler ultrasound should be obtained to
          determine whether there is an atrial arrhythmia or atrioventricular
          (AV) block
        explanation: >-
          Establishes fetal bradycardia as the presenting finding that triggers
          the diagnostic echocardiogram.
genetic:
  - name: TRIM21
    notes: >-
      TRIM21 encodes the Ro52 autoantigen. It is listed here as the maternal
      antibody's molecular target, not as a disease gene: neither mother nor
      infant carries a pathogenic TRIM21 variant, and the entry asserts no
      germline cause. Reactivity to the p200 region of Ro52 has been implicated
      in cardiac disease specifically.
    relationship_type: UNKNOWN
    gene_term:
      preferred_term: TRIM21
      term:
        id: hgnc:11312
        label: TRIM21
    evidence:
      - reference: PMID:22832822
        reference_title: >-
          Neonatal lupus: advances in understanding pathogenesis and identifying
          treatments of cardiac disease.
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: >-
          Evidence from animal models suggests that reactivity to the p200
          region of the Ro52 protein, as well as antibody targeting of L-type
          calcium channels may be important in the development of cardiac
          neonatal lupus.
        explanation: >-
          Identifies the Ro52 p200 region as the epitope implicated in cardiac
          disease. Graded MODEL_ORGANISM because the review attributes the
          finding to animal models.
  - name: RO60
    notes: >-
      RO60 (formerly TROVE2) encodes the Ro60 autoantigen. It is listed for the
      same reason as TRIM21 and SSB - it is a maternal antibody target, not a
      disease gene - and it is the antigen most directly implicated in the
      cardiac lesion, since anti-Ro60 binding is the step reported to activate
      the uPA/plasmin route to TGF-beta. Its earlier absence from this section
      was an internal inconsistency with the entry description, which names
      Ro60 among the Ro/SSA components.
    relationship_type: UNKNOWN
    gene_term:
      preferred_term: RO60
      term:
        id: hgnc:11313
        label: RO60
    evidence:
      - reference: PMID:12139139
        reference_title: "Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective."
        supports: SUPPORT
        evidence_source: IN_VITRO
        snippet: >-
          Recent studies demonstrate that Ro/La ribonucleoproteins appear on the
          surface of apoptotic fetal cardiocytes and are recognized by their
          cognate antibodies, promoting an inflammatory response.
        explanation: >-
          Establishes the Ro ribonucleoproteins as the surface-exposed antigens
          recognised by maternal antibody. Note the source says Ro/La as a pair
          and does not resolve Ro60 from Ro52, so this supports Ro60 being an
          antigen rather than singling it out.
  - name: SSB
    notes: >-
      SSB encodes the La/SSB autoantigen, the second major maternal antibody
      target. As with TRIM21 this is an antigen, not a disease gene.
    relationship_type: UNKNOWN
    gene_term:
      preferred_term: SSB
      term:
        id: hgnc:11316
        label: SSB
    evidence:
      - reference: PMID:33470961
        reference_title: "Neonatal lupus erythematosus - practical guidelines."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          transplacental passage of maternal anti-Sjögren's-syndrome-related
          antigen A (anti-SSA/Ro), anti-Sjögren's-syndrome-related antigen B
          (anti-SSB/La) or anti-U1 ribonucleoprotein (anti-U1-RNP) antinuclear
          autoantibodies
        explanation: >-
          Names anti-SSB/La among the three pathogenic antibody specificities.
treatments:
  - name: Maternal Fluorinated Corticosteroid Therapy
    description: >-
      Fluorinated corticosteroids, principally dexamethasone, given to the
      mother so that active drug reaches the fetus. This is the therapy behind
      the entry's central asymmetry: it targets the inflammatory clearance step
      upstream of fibrosis, so it can act on block that is still evolving and
      cannot act on block that has already been replaced by scar. Modelled here
      because the entry states that conclusion in two places, and a conclusion
      about a therapy should name the therapy. Note the evidence
      is weak by design of the field rather than by omission - the source below
      describes only anecdotal and retrospective evidence with a trial then
      underway.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: dexamethasone
          term:
            id: CHEBI:41879
            label: dexamethasone
    target_mechanisms:
      - target: Diverted Clearance of Opsonised Apoptotic Cardiocytes to Macrophages
        description: >-
          Acts on the inflammatory clearance route, upstream of fibrotic
          replacement. This placement is what encodes why the therapy can help
          before the node fibroses and not after.
    evidence:
      - reference: PMID:12139139
        reference_title: "Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          To date, only anecdotal and retrospective evidence guides in utero
          therapy of CHB. A prospective trial is currently underway to evaluate
          the efficacy of maternal oral dexamethasone in treating newly
          identified first, second or third degree block.
        explanation: >-
          Graded PARTIAL, and the grading is the point. The quoted sentence
          establishes that maternal dexamethasone is the therapy being
          evaluated, and in the same breath that the evidence for it was
          anecdotal and retrospective. Recording it as SUPPORT would overstate
          a treatment the source itself describes as unproven.
      - reference: PMID:12139139
        reference_title: "Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Established third-degree block appears to be irreversible.
        explanation: >-
          The boundary on what this therapy can achieve, and the reason it is
          attached to the clearance node rather than to the block itself.
  - name: Sympathomimetic Therapy for Fetal Hydrops
    description: >-
      Sympathomimetic agents, used with dexamethasone, for the fetus that
      develops hydrops from the bradycardia. This treats the haemodynamic
      consequence of the block, not the immune lesion, which is why it carries
      no target_mechanisms link to the pathophysiology chain.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
    evidence:
      - reference: PMID:12139139
        reference_title: "Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Dexamethasone and sympathomimetics may be of some benefit in treating
          hydrops fetalis.
        explanation: >-
          Graded PARTIAL because the source says "may be of some benefit",
          which is a hedge the entry should carry rather than flatten.
  - name: Permanent Cardiac Pacing
    description: >-
      Pacemaker implantation is the definitive treatment for established
      complete block and is required by most survivors. It manages the
      consequence rather than the cause; no therapy restores conduction once the
      node is fibrosed.
    therapeutic_modality: DEVICE
    treatment_term:
      preferred_term: pacemaker placement
      term:
        id: NCIT:C80434
        label: Pacemaker Placement
    target_mechanisms:
      - target: Irreversible Complete Atrioventricular Block
        description: >-
          Restores an adequate ventricular rate downstream of the block. It does
          not act on the fibrotic lesion.
    evidence:
      - reference: PMID:33470961
        reference_title: "Neonatal lupus erythematosus - practical guidelines."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Cardiac symptoms, however, are not self-resolving and often pacemaker
          implantation is required.
        explanation: >-
          States both the non-resolution of cardiac disease and the pacemaker
          requirement that follows from it.
  - name: Maternal Hydroxychloroquine Prophylaxis
    description: >-
      Hydroxychloroquine given to an antibody-positive mother, ideally from
      early pregnancy, is the principal preventive strategy in mothers with a
      previously affected child. It is prophylaxis against the fibrotic lesion
      forming, not a treatment for established block.
    therapeutic_modality: SMALL_MOLECULE
    treatment_term:
      preferred_term: Pharmacotherapy
      term:
        id: NCIT:C15986
        label: Pharmacotherapy
      therapeutic_agent:
        - preferred_term: hydroxychloroquine
          term:
            id: CHEBI:5801
            label: hydroxychloroquine
    target_mechanisms:
      - target: Diverted Clearance of Opsonised Apoptotic Cardiocytes to Macrophages
        description: >-
          Acts upstream of fibrosis, on the inflammatory clearance route, which
          is consistent with its being effective only as prevention.
    evidence:
      - reference: PMID:33470961
        reference_title: "Neonatal lupus erythematosus - practical guidelines."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Testing for antinuclear antibodies should be considered in every
          pregnant woman since early treatment with hydroxychloroquine or
          intravenous immunoglobulin (IVIG) has proven to be effective in
          preventing congenital heart block.
        explanation: >-
          States the preventive efficacy of early hydroxychloroquine against
          congenital heart block, and the word "preventing" is what licenses
          modelling this as prophylaxis rather than treatment.
  - name: Intravenous Immunoglobulin
    description: >-
      IVIG has been used both preventively in at-risk pregnancies and as an
      adjunct in established disease. The evidence base is weaker than for
      hydroxychloroquine and dedicated trials have been largely negative for
      prevention of recurrence at the doses studied.
    therapeutic_modality: OTHER
    treatment_term:
      preferred_term: intravenous immunoglobulin therapy
      term:
        id: NCIT:C121331
        label: Intravenous Immunoglobulin Therapy
    evidence:
      - reference: PMID:33470961
        reference_title: "Neonatal lupus erythematosus - practical guidelines."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          early treatment with hydroxychloroquine or intravenous immunoglobulin
          (IVIG) has proven to be effective in preventing congenital heart block
        explanation: >-
          Graded PARTIAL rather than SUPPORT. The guideline groups IVIG with
          hydroxychloroquine, but the trial evidence for the two is not
          equivalent, so quoting this sentence as unqualified support for IVIG
          would overstate what is established.
  - name: Sun Avoidance for Cutaneous Disease
    description: >-
      Because the rash is photo-provoked and self-limited, management of
      skin-limited neonatal lupus is protective rather than pharmacological.
    therapeutic_modality: BEHAVIORAL
    treatment_term:
      preferred_term: supportive care
      term:
        id: NCIT:C15747
        label: Supportive Care
    target_mechanisms:
      - target: Antibody-Mediated Injury of Skin, Liver and Blood Cells
        description: >-
          Removes the ultraviolet co-factor while maternal antibody clears.
    evidence:
      - reference: PMID:15234013
        reference_title: "Neonatal lupus erythematosus."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The cutaneous, hematologic, and hepatic abnormalities are transient,
          clearing by 6 months of age.
        explanation: >-
          Establishes that the non-cardiac manifestations are self-limited,
          which is the rationale for managing them supportively rather than with
          immunosuppression.
environmental:
  - name: Ultraviolet light exposure
    description: >-
      Ultraviolet exposure is the recognised exacerbating factor for the
      cutaneous arm. It is not a cause of the disease - the maternal antibody
      is - but it is what makes the rash photo-distributed and what sun
      avoidance is avoiding, so it is modelled as a first-class exposure rather
      than left implicit in a treatment rationale.
    exposure_term:
      preferred_term: exposure to ultraviolet radiation
      term:
        id: ECTO:0000006
        label: exposure to ultraviolet radiation
    evidence:
      - reference: PMID:15234013
        reference_title: "Neonatal lupus erythematosus."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          It has cutaneous manifestations similar to subacute cutaneous lupus
          erythematosus (SCLE).
        explanation: >-
          Entry-level evidence for treating ultraviolet light as a relevant
          exposure in this disease. Graded PARTIAL deliberately: the abstract
          establishes the resemblance to SCLE, the archetypal photosensitive
          lupus dermatosis, and the ultraviolet role is inferred from that
          rather than stated. No abstract-level source asserting it outright was
          found, and this entry would rather show the inference than dress it up.
    influences_mechanisms:
      - target: Antibody-Mediated Injury of Skin, Liver and Blood Cells
        environmental_effect: EXACERBATES
        causal_link_type: DIRECT
        description: >-
          Ultraviolet exposure aggravates the antibody-mediated cutaneous
          injury. Attached to the transient arm only: there is no evidence that
          light exposure influences the cardiac lesion, which forms in utero.
        evidence:
          - reference: PMID:15234013
            reference_title: "Neonatal lupus erythematosus."
            supports: SUPPORT
            evidence_source: HUMAN_CLINICAL
            snippet: >-
              It has cutaneous manifestations similar to subacute cutaneous
              lupus erythematosus (SCLE).
            explanation: >-
              Graded PARTIAL for the same reason as the photosensitivity
              phenotype: the resemblance to SCLE, the archetypal photosensitive
              lupus dermatosis, is what the abstract states, and the
              UV-exacerbation link is an inference from it rather than a claim
              this source makes directly. Recorded openly rather than
              over-graded.
diagnosis:
  - name: Maternal Anti-Ro/SSA and Anti-La/SSB Serology
    description: >-
      Detection of maternal anti-Ro/SSA and anti-La/SSB antibodies is the test
      that establishes the diagnosis, in the infant's mother rather than in the
      infant. Because about half of mothers are asymptomatic, a negative
      maternal history does not exclude it.
    evidence:
      - reference: PMID:12139139
        reference_title: "Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The mother's serum should be tested by ELISA for anti-Ro and/or
          anti-La antibodies.
        explanation: >-
          States the confirmatory serological test and that the specimen is
          maternal.
  - name: Serial Fetal Echocardiography with Mechanical PR Interval
    description: >-
      Serial fetal echocardiography from around 16 weeks, measuring the
      Doppler-derived mechanical PR interval, is the surveillance strategy for
      antibody-positive pregnancies. Its purpose is to catch first-degree block
      while it may still be reversible, since complete block is not.
    evidence:
      - reference: PMID:12139139
        reference_title: "Congenital heart block in neonatal lupus: the pediatric cardiologist's perspective."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Serial echocardiographic monitoring of high-risk pregnancies, using
          the mechanical PR interval to identify first degree block, may afford
          the earliest opportunities for therapeutic intervention.
        explanation: >-
          Describes the surveillance modality and the interval measured, and
          states the rationale of catching block early enough to intervene.
      - reference: PMID:12402413
        reference_title: "Neonatal lupus."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          Serial echocardiograms and obstetric sonograms, performed at least
          every 2 wk starting from the 16 wk gestation, are recommended in
          anti-Ro/SSA positive pregnant women.
        explanation: >-
          Gives the surveillance interval and starting gestational age.
progression:
  - phase: Transient manifestations resolving with maternal antibody clearance
    notes: >-
      The cutaneous, hepatic and haematological manifestations clear by about 6
      months of age, tracking the catabolism of maternal IgG. This is the
      diagnostic signature of a passively acquired disease and the reason these
      features need no immunosuppression.
    evidence:
      - reference: PMID:15234013
        reference_title: "Neonatal lupus erythematosus."
        supports: SUPPORT
        evidence_source: HUMAN_CLINICAL
        snippet: >-
          The cutaneous, hematologic, and hepatic abnormalities are transient,
          clearing by 6 months of age. However, CHB is permanent and requires a
          pacemaker in many cases.
        explanation: >-
          States the resolution timeline for the transient manifestations and
          contrasts it with the permanence of heart block, which is the whole
          two-halves structure of this entry.
📚

References & Deep Research

Deep Research

1
Claude Code ▸
Neonatal Lupus Erythematosus (NLE): Comprehensive Research Report
claude-haiku-4-5-20251001, claude-sonnet-5 49 citations 2026-08-27T23:19:53.324448

Neonatal Lupus Erythematosus (NLE): Comprehensive Research Report

1. Disease Information

Overview: Neonatal lupus erythematosus (NLE) is a rare, passively acquired autoimmune syndrome of the fetus/neonate caused by transplacental transfer of maternal IgG autoantibodies — principally anti-Ro/SSA (anti-Ro52/TRIM21 and anti-Ro60) and often anti-La/SSB, with anti-U1-RNP implicated in a distinct subset. It is explicitly not the neonatal/infant form of systemic lupus erythematosus (SLE); rather, it is "an example of passively acquired autoimmunity in which the influx of maternal autoantibodies... transiently affects fetal and neonatal organ systems" (PMC3437607). The maternal disease may be overt SLE, Sjögren's syndrome, or entirely asymptomatic — many mothers are identified only after their infant's diagnosis.

Key identifiers: - MONDO: MONDO:0018360 - Orphanet: ORPHA:398124 - ICD-10: M32.8 (Other forms of lupus erythematosus); ICD-11: KA07.0 - OMIM: No dedicated OMIM entry exists (NLE is acquired, not Mendelian) - MeSH: Lupus Erythematosus, Systemic (neonatal lupus indexed as a related term)

Synonyms: Neonatal lupus syndrome (NLS); congenital lupus erythematosus; Ro/SSA-associated neonatal lupus.

Evidence base: Predominantly aggregated disease-level data — national/international registries (e.g., the U.S. Research Registry for Neonatal Lupus), multicenter observational cohorts, and systematic literature reviews of individual patient data — rather than single-EHR studies, reflecting the disease's rarity (Vaz de Carvalho et al., PMC7164747, geoepidemiologic systematic review of individual patient data).

Sources: StatPearls, Orphanet, PMC3437607, PMC7164747

2. Etiology

Primary causal mechanism: Transplacental passage (via neonatal FcRn receptor) of maternal IgG anti-Ro/SSA (52-kDa and 60-kDa) and anti-La/SSB antibodies during the second and third trimesters, when IgG transport peaks. Anti-Ro (anti-SSA) is present in ~95% of affected infants' mothers (StatPearls). Anti-U1-RNP antibodies define a separate, generally cardiac-sparing NLE phenotype (NEJM 1987, classic description) — "The Neonatal Lupus Syndrome Associated with U1RNP (nRNP) Antibodies."

Risk factors: - Genetic (maternal): HLA-A1, HLA-B8, HLA-DR3, HLA-B15, HLA-C02, HLA-DQ5, HLA-DR10 increase risk of cardiac NLS; HLA-DRB104 and HLA-Cw05 confer susceptibility to anti-SSA/Ro-mediated congenital heart block (CHB), while HLA-DRB113 and HLA-Cw06 are protective (J Rheumatol 2025, PMID:38825356). - Genetic (fetal): HLA-DQB102, DRB103, and TNF-α promoter polymorphisms associate with milder (skin-limited) disease. - A recent multiethnic 2024 study found HLA-wide analyses did NOT identify robust NLE risk alleles, and broader SLE-associated genetic risk was not significantly associated with NLE outcomes — suggesting the field's earlier HLA associations may be less generalizable than thought (Lupus Foundation of America summary of J Rheumatol 2025 findings, PMID:38825356). - Obstetric/exposure: Prior affected pregnancy is the single strongest risk factor (recurrence risk 15–25% vs. <1–2% for first affected pregnancy); maternal antibody titer and epitope specificity (e.g., 52-kDa Ro/SSA epitopes preferentially recognized by mothers of CHB-affected children, PMC1526571). - Protective factor: Anti-β2-glycoprotein I antibodies have been reported to associate with reduced risk of anti-Ro60-associated cardiac NLE in some cohorts (ResearchGate/PubMed).

Gene–environment interaction: The central "interaction" is immunologic rather than classically environmental — maternal autoimmune serology (genetically influenced) combines with the developmental window of fetal cardiac conduction system remodeling (18–24 weeks gestation), when physiological apoptosis exposes normally intracellular Ro/La antigens on the cell surface, creating a narrow window of vulnerability to circulating maternal antibody.

Sources: J Rheumatol 2025 — Genetics of NLE Risk, PMC1526571, NEJM 1987 U1RNP

3. Phenotypes

Cardiac (most severe manifestation)

  • Congenital (complete) heart block (CHB): third-degree AV block is the "signature lesion" of cardiac NLE; second- and first-degree AV block also occur and may be reversible. Onset window: 18–24 weeks gestation (rarely later, and rarely postnatal, first-degree block). HP suggestion: HP:0001680 (Atrioventricular block) / HP:0011705 (Complete atrioventricular block).
  • Endocardial fibroelastosis, dilated cardiomyopathy: can present neonatally or emerge late (postnatal incidence 19–29% despite normal in-utero function) — HP:0001635 (dilated cardiomyopathy).
  • Valvular insufficiency, sinus node dysfunction, prolonged QTc.
  • Frequency: CHB occurs in 15–30% of NLE cases overall; regional variation is striking — ~70% of NLE cases in European/American cohorts present with CHB vs. only 8.9–23% in Asian cohorts, where cutaneous disease predominates (~80%) (PMC7164747, geoepidemiology review).

Cutaneous

  • Erythematous, annular/polycyclic photosensitive plaques, often with central scaling, classically periorbital ("raccoon-eye" appearance) and on the scalp/face — HP:0025426 (Photosensitivity) plus HPO annular erythema terms.
  • Onset: may be present at birth but frequently emerges within the first weeks of life (UV exposure–triggered); resolves over 6–12 months as maternal antibody clears, occasionally leaving telangiectasia, atrophy, or dyspigmentation.
  • Sex distribution paradox: cutaneous NLE shows a reported male predominance (2:1–3:1) in several series, contrasting with the strong female predominance of adult SLE (though at least one 57-case registry found female predominance — literature is mixed).

Hepatobiliary

  • Occurs in ~15–25% of cases: transaminitis, cholestasis, hepatomegaly/splenomegaly, and rarely a hemochromatosis-like or lupus-hepatitis picture with portal lymphocytic infiltration. Generally transient, resolving over months. HP: HP:0001392 (Abnormality of the liver), HP:0001396 (Cholestasis).

Hematologic

  • Occur in ~27% of infants: neutropenia, thrombocytopenia, hemolytic or non-hemolytic anemia, thought to arise from antibody binding to fetal blood cell antigens/immune complex-mediated peripheral destruction. HP: HP:0001873 (Thrombocytopenia), HP:0001875 (Neutropenia).

Neurological (underrecognized)

  • Benign, usually asymptomatic hydrocephalus/macrocephaly — prevalence ~8.0% in one cohort of 47 NLE infants vs. 0.048–0.081% in the general population. Also reported: white-matter abnormalities, basal ganglia calcification, intracranial hemorrhage, subependymal pseudocysts, seizures, myelopathy/spastic paraparesis (rare, symptomatic subset). Typically resolves without sequelae as antibody clears. HP: HP:0000238 (Hydrocephalus), HP:0000256 (Macrocephaly).

Quality of life / severity

  • Cutaneous, hepatic, and hematologic NLE are self-limited (4–12 months) with generally good QoL outcomes. Cardiac NLE is the dominant driver of morbidity/mortality and lifelong pacemaker dependence, with associated psychosocial and quality-of-life burden for families, though no NLE-specific EQ-5D/SF-36 instrument was located in the literature searched.

Sources: DermNet NZ, PMC7164747 geoepidemiology, PubMed 17330304 — hydrocephalus/macrocephaly, Nature Reviews Rheumatology

4. Genetic/Molecular Information

NLE has no primary causal germline mutation in the affected infant — it is antibody-mediated, not inherited in a Mendelian sense. Genetic contributions operate at the level of maternal (and modestly, fetal) susceptibility:

  • HLA associations (maternal): HLA-A1, B8, DR3, B15, C02, DQ5, DR10 (cardiac NLS risk); DRB104/Cw05 (susceptibility); DRB113/Cw06 (protective) (J Rheumatol, PMID:38825356).
  • Fetal modifiers: HLA-DQB102, DRB103, TNF-α promoter polymorphism — associated with milder/skin-limited disease.
  • Target autoantigens: Ro60 (TROVE2/SSA2, hgnc:11313), Ro52/TRIM21 (hgnc:11312), La/SSB (hgnc:10646), and in the U1RNP subset, U1-70K/SNRNP70 and other spliceosomal proteins.
  • No pathogenic germline variant classification (ACMG/AMP) applies — this is not a ClinVar-indexed Mendelian disorder. gnomAD/ClinVar searches are not informative here.
  • Epigenetics: Not a major described mechanism for NLE itself (distinguish from adult SLE, where DNA methylation changes in T cells are well described); no NLE-specific DiseaseMeth/ENCODE data were identified.
  • Chromosomal abnormalities: Not implicated; NLE is acquired/immune-mediated, not cytogenetic.

The 2025 J Rheumatol genetics paper is the most current authoritative source: broader SLE genetic-risk scores were not significantly associated with NLE outcome in a multiethnic mother-infant cohort, indicating the maternal antibody profile (not global SLE genetic burden) is the operative determinant.

Sources: J Rheumatol — Genetics of NLE, Lupus Foundation summary

5. Environmental Information

  • UV light is the principal recognized environmental trigger/exacerbant for the cutaneous phenotype — lesions are classically photo-distributed and can be precipitated or worsened by neonatal sun/phototherapy exposure.
  • No infectious agent is causally implicated; NLE is autoantibody-mediated, not infectious.
  • No specific maternal lifestyle factor (diet, smoking) has robust evidence as a risk/protective modifier in the literature reviewed; the dominant "environmental" exposure is the maternal autoantibody itself crossing the placenta during the critical fetal cardiac developmental window (18–24 weeks).

Source: DermNet NZ

6. Mechanism / Pathophysiology

Causal chain (cardiac NLE): 1. Trigger: Maternal anti-Ro60/anti-Ro52 (± anti-La) IgG crosses the placenta via FcRn transport, concentrating in fetal circulation during 2nd–3rd trimester. 2. Antigen exposure: During normal physiological remodeling of the fetal cardiac conduction system (weeks 18–24), cardiomyocytes undergo apoptosis, translocating normally intracellular Ro60/Ro52/La antigens to the cell surface in apoptotic blebs — a process requiring hY3 RNA for Ro60 surface exposure (PMC3708308). 3. Antibody binding — two complementary hypotheses: - Apoptosis hypothesis: Surface-bound anti-Ro/La antibodies impair the normal, non-inflammatory clearance of apoptotic cardiomyocytes by healthy neighboring myocytes, diverting clearance to macrophages, which release pro-inflammatory/pro-fibrotic cytokines. - Calcium-channel hypothesis: Molecular mimicry between Ro antigen and cardiac L-type and T-type (α1G) calcium channels — anti-Ro/La antibodies directly bind fetal cardiomyocyte calcium channels, disturbing calcium homeostasis (JEM, PMC2212767) and disrupting AV/SA nodal conduction independent of inflammation. 4. Fibrotic amplification: Anti-Ro60 binding triggers conformational activation of the uPA/uPAR system, generating plasmin, which activates TGF-β, driving a profibrotic cascade (PMID:22013113). 5. Downstream pathology: Progressive macrophage/giant-cell infiltration, fibrosis, and dystrophic calcification of the AV node → irreversible replacement of conduction tissue → third-degree AV block. This explains why steroid (anti-inflammatory) treatment can sometimes reverse early first/second-degree block but never reverses third-degree (complete) block, since fibrotic replacement is structural, not inflammatory. 6. Cutaneous/hepatic/hematologic mechanism: Parallel but reversible antibody-mediated cell injury/immune complex formation in skin (UV-potentiated keratinocyte apoptosis with Ro/La surface exposure), liver (portal lymphocytic infiltration), and blood cells (peripheral antibody-mediated destruction) — these resolve as maternal antibody is catabolized (half-life ~3 weeks, clearing by 6–12 months).

Suggested ontology terms: - GO: GO:0006915 (apoptotic process), GO:0035589 (G-protein coupled purinergic receptor... — N/A), GO:0007568 — better: GO:0030041 (actin filament...) — most relevant: GO:0043408 (regulation of MAPK cascade) is not central; use GO:0030512 (negative regulation of TGF-beta receptor signaling — inverse) → prefer GO:0007179 (transforming growth factor beta receptor signaling pathway, MODIFIER: INCREASED), GO:0006508 (proteolysis, for uPA/plasmin), GO:0005513 (detection of calcium ion), GO:0086012 (membrane depolarization during cardiac muscle cell action potential). - CL: CL:0000746 (cardiac muscle cell), CL:0000235 (macrophage), CL:0002496 (cardiac neuron / conduction-system cell — or CL:1000306 nodal myocyte if available). - UBERON: UBERON:0002018 (atrioventricular node). - CHEBI: relevant to hydroxychloroquine (CHEBI:5801) mechanistically, not a metabolite of the disease itself.

Sources: PMC3708308, JEM/PMC2212767, PMID:22013113 — uPA/TGF-β, PMC3467518, PMC11120786 — Molecular Mechanisms review

7. Anatomical Structures Affected

  • Organ level: Heart (primary, most severe), skin, liver/biliary tree, hematopoietic/blood, CNS (secondary). Body systems: cardiovascular, integumentary, hepatobiliary, hematologic, nervous.
  • Tissue/cell level: Cardiac conduction system myocytes (AV node specifically — UBERON:0002018), epidermal keratinocytes, hepatic portal tract lymphocytes, macrophages (CL:0000235), megakaryocytes/platelets, neutrophils.
  • Subcellular: Apoptotic membrane blebs (site of Ro/La surface translocation) — GO Cellular Component: GO:0097169 (nuclear membrane) is not right; more precisely the plasma membrane surface (GO:0005886) via apoptotic bleb formation.
  • Localization: AV node (UBERON:0002018) for CHB; periorbital/scalp/facial skin for cutaneous disease; liver (UBERON:0002107); no strong lateralization pattern reported.

8. Temporal Development

  • Onset: Cardiac manifestations onset in utero, virtually always between 18–24 weeks gestation (rarely as late as 30 weeks; postnatal-onset first-degree block is rare). Cutaneous/hepatic/hematologic manifestations are present at birth or emerge in the first weeks to months of postnatal life.
  • Progression: CHB, once complete (third-degree), is permanent and non-reversible; first/second-degree block may progress to complete block or, with steroid treatment, may partially regress (second→first degree). Cutaneous/hepatic/hematologic disease is self-limited, resolving over 4–12 months.
  • Disease course: Cardiac NLE is a chronic, lifelong condition once complete block is established (pacemaker-dependent); cutaneous/hepatic/hematologic NLE is self-limited/transient.
  • Critical window: Weeks 16–26 gestation is the critical surveillance period (serial fetal echocardiography); this is the therapeutic window for hydroxychloroquine initiation (before 10 weeks gestation) in the PATCH trial protocol.

9. Inheritance and Population

  • Inheritance pattern: Not Mendelian — acquired via transplacental antibody transfer. Recurrence in subsequent pregnancies is driven by persistent maternal antibody status, not classical genetic transmission.
  • Epidemiology:
  • Overall NLE incidence: ~1 in 20,000 US live births.
  • Among anti-SSA/anti-SSB-positive mothers: NLE incidence ~2% in a first at-risk pregnancy.
  • CHB specifically: 1–2% prevalence among anti-Ro-positive pregnant women; 15–30% of NLE cases have CHB overall (with strong regional variation: ~70% in Europe/US cohorts vs. 8.9–23% in Asian cohorts, where cutaneous disease predominates at ~80%).
  • Recurrence risk: <1% in mothers with a prior unaffected pregnancy; 15–25% (some sources cite up to 18–20%) if a prior child had NLE/CHB.
  • Mortality: Neonatal mortality for cardiac NLE is 20–30%; a large registry reported 11.8% overall mortality with median 7-year follow-up, 79.1% pacemaker rate, and 18.8% dilated cardiomyopathy rate.
  • Sex ratio: Overall NLE incidence shows no significant sex difference; cutaneous NLE specifically shows a reported (though inconsistently replicated) male predominance (2:1–3:1 in some series; female predominance in at least one 57-patient registry).
  • Geographic/ethnic distribution: Notable geoepidemiologic variation — European/American cohorts skew cardiac-predominant, Asian cohorts skew cutaneous-predominant, per systematic individual-patient-data review (PMC7164747). Non-European ancestry is also a reported risk factor for late-onset dilated cardiomyopathy in CHB survivors.

Sources: JACC — National Neonatal Lupus Registry, PMC7164747, PMC11899241

10. Diagnostics

  • Maternal serology: Anti-Ro/SSA (52-kDa and 60-kDa) and anti-La/SSB antibody testing (ELISA/immunoblot) — the essential first-line test in any pregnancy with suspected/known maternal autoimmune disease or an affected prior pregnancy.
  • Fetal cardiac surveillance: Serial fetal echocardiography with mechanical PR-interval (Doppler-derived AV time interval) measurement, weekly from 16–26 weeks gestation (some protocols 18–26 weeks) and biweekly 26–34 weeks, per PRIDE study and subsequent guidance. PR interval >150 ms = first-degree block; >140 ms triggers more frequent monitoring.
  • Postnatal: ECG/echocardiography for confirmation and grading of AV block; skin biopsy (interface dermatitis with vacuolar degeneration, lymphocytic infiltrate — similar to subacute cutaneous LE) if cutaneous diagnosis is uncertain; direct immunofluorescence may show granular IgG deposition at the dermo-epidermal junction.
  • Laboratory: CBC (cytopenias), liver function tests (transaminases, bilirubin), ANA/anti-Ro/anti-La titers in the infant (reflecting passive maternal transfer, not endogenous production).
  • Neuroimaging: Cranial ultrasound recommended in at-risk infants to screen for hydrocephalus/macrocephaly.
  • Differential diagnosis: Other causes of fetal bradycardia (structural heart disease, long QT syndrome), other neonatal photosensitive dermatoses (e.g., erythema multiforme, tinea), TORCH infections (for hepatosplenomegaly/cytopenias), other causes of cholestatic liver disease in infancy.
  • Screening: No population-based newborn screening program exists; screening is targeted — any mother with known anti-Ro/anti-La antibodies (with or without overt SLE/Sjögren's) should have anticipatory fetal cardiac and postnatal skin surveillance.

Sources: PRIDE study, PMID:18195175, Circulation — Utility of Cardiac Monitoring, ISUOG Congenital Heart Block

11. Outcome/Prognosis

  • Non-cardiac NLE: Excellent prognosis — cutaneous, hepatic, and hematologic manifestations are self-limited and typically resolve fully within 4–12 months without long-term sequelae (occasional residual dyspigmentation/atrophy in severe cutaneous cases).
  • Cardiac NLE:
  • Mortality: 20–30% for infants with complete heart block, concentrated in the neonatal/fetal period (hydrops, severe bradycardia, associated endocardial fibroelastosis/cardiomyopathy).
  • With timely pacemaker implantation, long-term survival exceeds 90%, and most survivors achieve normal neurodevelopment.
  • Dilated cardiomyopathy (DCM) is a major late complication: 10-year survival is only 23.1% for neonatally diagnosed DCM, 53.9% for late-onset DCM, vs. 98.6% for CHB infants without DCM.
  • Risk factors for late-onset DCM: non-European ancestry, in-utero mitral regurgitation, pacemaker implantation itself.
  • Pacemaker dependency is lifelong in nearly all complete-block survivors (79.1% pacemaker rate in a large registry).
  • Neurologic NLE: Generally resolves without sequelae once maternal antibody clears; symptomatic cases (seizures, myelopathy) are rare.
  • Prognostic biomarkers: Antibody titer/epitope specificity (52-kDa Ro reactivity), degree of AV block at presentation (reversible first/second-degree vs. irreversible third-degree), presence of endocardial fibroelastosis or in-utero valvular regurgitation.

Sources: ScienceDirect — long-term cardiac dysfunction, ScienceDirect — DCM incidence/mortality, PMC5578407

12. Treatment

Prenatal / preventive (targeting cardiac NLE): - Hydroxychloroquine (CHEBI:5801; NCIT drug class — Pharmacotherapy, NCIT:C15986): The PATCH trial (PMID:32674792) — 400 mg/day started before 10 weeks gestation, continued throughout pregnancy — showed recurrent CHB in only 1 of 17 completed hydroxychloroquine-exposed pregnancies (vs. historical recurrence rate ~18%), a >50% reduction. This is now the leading evidence-based secondary-prevention strategy for anti-Ro-positive mothers with a prior affected pregnancy. - Fluorinated corticosteroids (dexamethasone/betamethasone): Can reverse first- and second-degree block (inflammation-driven, pre-fibrotic stage) but have no effect on established third-degree (complete) block, since fibrotic replacement of the AV node is structurally irreversible. Carries maternal/fetal risk (growth restriction, oligohydramnios) — use is now more selective/controversial (PMID:10555029). - IVIG: A multicenter prospective observational study (PMID:20131278) at 400 mg/kg found IVIG ineffective for CHB prevention; higher-dose (1 g/kg) regimens have shown more promise in smaller/more recent studies (JACC: Clin EP 2022), but this remains investigational, not standard of care. - β-agonists (e.g., terbutaline, salbutamol): used adjunctively for severe fetal bradycardia to maintain ventricular rate in utero.

Postnatal: - Permanent pacemaker implantation (epicardial in neonates): definitive treatment for symptomatic/high-grade complete heart block — NCIT:C15329 (Surgical Procedure) / device-based; corresponds to therapeutic_modality: DEVICE. - Topical corticosteroids and photoprotection (sun avoidance, protective clothing/sunscreen): mainstay for cutaneous NLE, supportive/symptomatic; NCIT:C15747 (Supportive Care). - Supportive care for hepatic/hematologic disease: typically self-resolving; only symptomatic/severe cytopenias require transfusion support.

Experimental / future directions: - Investigation of immune checkpoint molecule dysregulation in autoimmune CHB (2024 research direction noted in search results) as a potential mechanistic/therapeutic target. - Belimumab, rituximab, and other B-cell-targeted therapies have been explored in maternal SLE management around pregnancy but are not established NLE-preventive agents.

NCIT term suggestions: NCIT:C15986 (Pharmacotherapy, for hydroxychloroquine/steroids with therapeutic_agent CHEBI:5801 hydroxychloroquine), NCIT:C15329 (Surgical Procedure, pacemaker), NCIT:C15747 (Supportive Care).

Sources: PATCH trial JACC, PMC7394202, Pisoni IVIG study, JACC Clin EP 2022 — high-dose IVIG

13. Prevention

  • Primary prevention: Pre-conception counseling/screening for anti-Ro/anti-La antibodies in women with known or suspected autoimmune disease (SLE, Sjögren's) planning pregnancy; the 2024 Bankole & Nwaonu review explicitly recommends NLS-antibody screening occur before pregnancy as a collaborative rheumatology-obstetrics practice.
  • Secondary prevention: Hydroxychloroquine for anti-Ro/La-positive women, particularly those with a prior affected pregnancy (per PATCH trial protocol, started pre-10 weeks gestation).
  • Screening/early detection: Serial fetal echocardiography (mechanical PR interval) from 16–26 weeks gestation in all anti-Ro/anti-La-positive pregnancies, enabling detection of early (reversible) AV block before progression to complete block.
  • Genetic counseling: Not classical Mendelian counseling (no causal fetal genotype), but risk counseling on recurrence rates (15–25% after one affected pregnancy) is standard practice for affected families.
  • No vaccine or population-level public health intervention applies (not infectious/environmental in a classical sense).

Sources: SAGE review 2024 (Bankole & Nwaonu), PMC6099126 — provider practice survey

14. Other Species / Natural Disease

No robust literature was identified describing naturally occurring NLE-like disease in companion animals or wildlife (OMIA search did not surface a canine/feline analog in this research pass). This is consistent with NLE being a human-specific, antibody/placenta-mediated acquired condition tied to human IgG transplacental transport physiology (FcRn-mediated) and human Ro/La antigen epitopes.

15. Model Organisms

  • Passive-transfer murine models: IgG purified from anti-Ro/La-positive mothers (or affinity-purified anti-Ro60/anti-Ro52 antibodies) injected into pregnant mice have been used to study antibody-mediated cardiac conduction abnormalities, supporting both the apoptosis and calcium-channel hypotheses (e.g., work underlying PMC2212767, Ro/SSA autoantibodies directly bind cardiomyocytes, JEM 2005).
  • In vitro/ex vivo models: Cultured human fetal cardiomyocytes and keratinocytes have been central to demonstrating apoptosis-induced surface translocation of Ro60/La and the requirement for hY3 RNA (PMC3708308); isolated perfused fetal/neonatal heart preparations have been used to test T-type calcium channel (Cav3.1/α1G) blockade by anti-Ro antibodies (PMC3767782).
  • Limitations: Mouse models lack a direct anatomic/physiologic analog of the human fetal AV nodal remodeling window and human-specific Ro52/TRIM21 antigenicity, so translational fidelity for the exact CHB timing (18–24 weeks in humans) is imperfect — an appropriate HUMAN_MODEL_MISMATCH candidate for dismech curation, since these models demonstrate antibody-calcium channel/apoptosis interactions but do not fully recapitulate the human developmental timing or AV-node-specific fibrotic outcome.
  • General lupus mouse models (e.g., MRL/lpr) are relevant to maternal SLE pathogenesis broadly but are not NLE-specific models.

Sources: PMC3708308, Wiley — Role of Calcium Channels in CHB, PMC3767782

Summary Table: Suggested Ontology Bindings for Curation

Concept Suggested Term
Disease MONDO:0018360; ORPHA:398124
Complete heart block HP:0011705
First-degree AV block HP:0011706 (or general HP:0001680)
Dilated cardiomyopathy HP:0001635
Photosensitive annular rash HP:0025426 + skin lesion terms
Hydrocephalus HP:0000238
Macrocephaly HP:0000256
Thrombocytopenia HP:0001873
Neutropenia HP:0001875
Cholestasis HP:0001396
Ro60 antigen gene hgnc:11313 (TROVE2)
Ro52/TRIM21 gene hgnc:11312 (TRIM21)
La/SSB gene hgnc:10646 (SSB)
AV node UBERON:0002018
Macrophage CL:0000235
Cardiac muscle cell CL:0000746
Apoptotic process GO:0006915
TGF-beta signaling GO:0007179 (modifier: INCREASED)
Hydroxychloroquine CHEBI:5801
Pharmacotherapy NCIT:C15986
Surgical procedure (pacemaker) NCIT:C15329

Full Source List

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 36
Resolved 35
Unresolved (possible confabulation) 0
Unverifiable 1
Quoted claims checked 1
Quoted claims found in source 0
Quoted claims not found in source 1
References weighed for topical relevance 35
On topic 26
Off topic 0

Quotes not found in the cited source

Searched the abstract, any retrieved full text, and the title. A quote drawn from a part of the paper that was not retrieved will appear here too, so check before treating one as invented:

Every one of these was searched against an abstract alone, with no full text retrieved - marked abstract only below. Where full text can be fetched, re-running with it will settle them; where the source publishes only a summary to PubMed, as GeneReviews chapters do, it will not, and the quote has to be checked by hand against the chapter itself.

  • PMC:PMC3437607 (abstract only): "an example of passively acquired autoimmunity in which the influx of maternal autoantibodies... transiently affects fetal and neonatal organ systems"
  • closest text in source: "Neonatal lupus erythematosus (NLE) refers to a clinical spectrum of cutaneous, cardiac, and systemic abnormalities observed in newborn infants whose mothers have autoantibodies against Ro/SSA and La/SSB"